Schweitzer Fachinformationen
Wenn es um professionelles Wissen geht, ist Schweitzer Fachinformationen wegweisend. Kunden aus Recht und Beratung sowie Unternehmen, öffentliche Verwaltungen und Bibliotheken erhalten komplette Lösungen zum Beschaffen, Verwalten und Nutzen von digitalen und gedruckten Medien.
Treatment of maladies by plants or extracts thereof is as old as the history of mankind. This is also true for fever and pain, two particularly frequent and inconvenient symptoms of acute illnesses but also typical for osteoarthritis and rheumatism, two examples of chronic painful diseases. Rheumatism was already known in old Egypt as seen from cartilage alterations in Egyptian mummies. The Egyptians were also aware of the pain-relieving effects of potions made from myrtle and willow leaves. Clay tablets from the Sumerian period also contained information about the use of willow leaves as medicines. Hippocrates recommended leaves of the willow tree for medical purposes about 400 BC. Pliny (compilations) and Dioscurides (Materia Medica) also recommended decocts of willow leaves or ash from willow bark for treatment of sciatica (lumbago) and gout at about 100 AC. Outside Europe, it were the Nama (Hottentots) in Southern Africa who had "for a long time" used tea made from bark of willow trees for treatment of rheumatic diseases (cited after Ref. [1]). This comment was made by Dr. Ensor from Cape Town (South Africa) in his reply to a publication of Dr. MacLagan in 1876 [2] describing for the first time positive experience with salicylates at 2 g/day for treatment of rheumatism.
The first known public communication on the medical use of willow bark extracts in modern times came from Reverend Edward Stone [3] from Chipping Norton (Oxfordshire, England). He treated some 50 cases of "aigues, fever, and intermitting disorders" with a redissolved powdered dry bark preparation of willow tree. The doses were about "20 gr(ains) [~1.3 g] to a dram of water every 4 hours." On June 2, 1763, he wrote a letter to the Earl of Macclesfield, the then President of the Royal Society in London, entitled "An account of the success of the bark of the willow in the cure of aigues." In this letter, he summarized his opinion about this treatment as follows:
.As this tree delights in moist or wet soil where agues chiefly abound, the general maxim, that many natural maladies carry their cure along with them or that their remedies lie not far from their causes, was so very apposite to this particular case, that I could not help applying it; and this might be the intention of providence here, I must own had some little weight with me..
After claiming to have obtained good results, he concluded:
.I have no other motives for publishing this valuable specific than that it may have a fair and full trial in all its variety of circumstances and situations, and that the world may reap the benefits accruing from it.
In 1828, the German pharmacist Johann Andreas Buchner was the first to prepare a yellowish mash with bitter taste from boiled willow bark, which he named Salicin, after the Latin word for willow (salix). He considered salicin as the active antipyretic ingredient of willow bark and recommended its use for treatment of fever. A similar conclusion had earlier been reached by the Italians Brugnatelli and Fontana in 1826 using a less purified preparation of willow bark. They also considered salicin as the active principal component of willow bark (cited after Ref. [4]). In 1830, the Frenchman Henry Leroux was the first to obtain salicin in crystalline form. Only 3 years later, in 1833, the pharmacist Merck in Darmstadt (Germany) announced highly purified salicin from willow bark for use as an antipyretic for half of the price of quinine (cited after Ref. [5]) - at that time a really attractive offer.
Salicin is not only the active antipyretic ingredient of willow bark but also the reason for its strong bitter taste and the irritation of stomach mucosa. Both limited its practical use. Salicin hydrolyzes in aqueous media to glucose and salicylic alcohol (saligenin). Saligenin has no bitter taste and can be easily oxidized to salicylic acid. Raffaele Piria, an Italian, was the first to successfully synthesize salicylic acid (acide salicique ou salicylique) from salicin in 1839 and also correctly determined the empirical formula C7H6O3. This led to the possibility of replacing the poorly palatable salicin by salicylic acid, for example, as a good water-soluble sodium salt. This became practically relevant after new and abundant natural sources for salicylates were detected. These included wintergreen oil obtained from the American Evergreen (Gaultheria procumbens) and spireic acid (acidum salicylicum) from the American teaberry (Spiraea ulmaria). Gaultheria oil (wintergreen oil) consists of about 99% of methyl salicylate from which free salicylic acid can easily be obtained. However, production of salicylates by plants is also an important defence mechanism in itself.
Efficient communication between the pest-colonized and noncolonized plants is vital for timely manifestation of defenses that restrict systemic spread of pests. Airborne signals are involved in these processes. Methyl salicylate is a volatile compound that is made by a number of plants and is suggested to act as a mobile airborne signal in plant defence by activation of systemic acquired resistance. This confers enhanced resistance against a broad spectrum of pathogens (Section 2.2.2) [6].
The modern pharmaceutical history of salicylates and its derivatives starts with the chemical synthesis of the compound. In 1859, Hermann Kolbe, a German and Professor of Chemistry in Marburg, produced the first fully synthetic salicylic acid from the already known decomposition products phenol and carbonic acid, that is, sodium phenolate and carbon dioxide. Kolbe then stimulated his assistant Rudolf Wilhelm Schmitt to further improve the technology, eventually resulting in doubling of the salicylic acid yield. Schmitt also elucidated the reaction kinetics. This base-promoted carboxylation of phenols under high pressure allowing the synthesis of salicylic acid derivatives is known since then as the "Kolbe-Schmitt reaction." Friedrich von Heyden, a student of Schmitt, was introduced to Kolbe who encouraged him to develop a procedure to make the compound on an industrial scale. Von Heyden was the first to receive a patent for this procedure. The development of an appropriate technology to synthesize large amounts of salicylate, independent of the limited availability of natural sources with varying contents and seasonal variations of the active ingredient, opened the door for its broader practical use and thus caused a massive drop in price: The price of 100 g of salicylic acid prepared from salicin from natural sources (gaultheria oil) dropped from 10 to 1 Taler/100 g (Dollar = American for Taler) for the chemical product made through Kolbe's synthesis (cited after Ref. [7]).
Von Heyden started the large-scale production of salicylic acid in the kitchen of his mansion, the "Villa Adolpha" in Dresden (Saxony). In 1874, the site was moved to Radebeul, a suburb west to Dresden, where he founded the factory "Salizylsäurefabrik Dr. von Heyden." This plant was extremely effective: After making 4 tons of salicylic acid in the first year, the annual production was increased to 25 tons only 4 years later and continued to grow steadily. Kolbe and von Heyden received patents for the synthesis of salicylate in many European countries and the United States [8]. Interestingly, after solving some legal issues, von Heyden's plant also produced the salicylic acid that was later used by Bayer to make aspirin [9].
After salicylate as a cheap chemical became available on an industrial scale, that is, in essentially unlimited amounts, the compound was tested for new practical applications. For example, salicylic acid was soon found to have antiseptic properties that could be used to preserve milk and meat. The compound was also recommended as an alternative to phenol (carbolic acid), which, was the antiseptic of choice in surgery those days. The antipyretic action of salicylate was for a time also attributed to its antiseptic activity, until it was shown that the sodium salt with little antiseptic properties was an equally effective antipyretic (cited after Ref. [1]). Importantly, salicylic acid was also studied as a potential drug in a large variety of diseases and thus became the first synthetic drug ever...
Dateiformat: ePUBKopierschutz: Adobe-DRM (Digital Rights Management)
Systemvoraussetzungen:
Das Dateiformat ePUB ist sehr gut für Romane und Sachbücher geeignet – also für „fließenden” Text ohne komplexes Layout. Bei E-Readern oder Smartphones passt sich der Zeilen- und Seitenumbruch automatisch den kleinen Displays an. Mit Adobe-DRM wird hier ein „harter” Kopierschutz verwendet. Wenn die notwendigen Voraussetzungen nicht vorliegen, können Sie das E-Book leider nicht öffnen. Daher müssen Sie bereits vor dem Download Ihre Lese-Hardware vorbereiten.Bitte beachten Sie: Wir empfehlen Ihnen unbedingt nach Installation der Lese-Software diese mit Ihrer persönlichen Adobe-ID zu autorisieren!
Weitere Informationen finden Sie in unserer E-Book Hilfe.